Lerisetron (BioDeep_00000180426)

   

human metabolite blood metabolite


代谢物信息卡片


1-benzyl-2-(piperazin-1-yl)-1H-1,3-benzodiazole

化学式: C18H20N4 (292.168788)
中文名称: 来立司琼
谱图信息: 最多检出来源 Homo sapiens(blood) 3.05%

分子结构信息

SMILES: C(N1C2=CC=CC=C2N=C1N1CCNCC1)C1=CC=CC=C1
InChI: InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2

描述信息

C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist
C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent
Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats[1].

同义名列表

3 个代谢物同义名

1-benzyl-2-(piperazin-1-yl)-1H-1,3-benzodiazole; 1-Benzyl-2-(1-piperazinyl)benzimidazole; Lerisetron



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Fátima Ortega, Antonio Quintana, Elena Suárez, John C Lukas, Nerea Jauregizar, Leire de la Fuente, Maria Luisa Lucero, Ana Gonzalo, Aurelio Orjales, Rosario Calvo. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model. Pharmaceutical research. 2005 Nov; 22(11):1769-82. doi: 10.1007/s11095-005-7750-6. [PMID: 16158214]
  • Nerea Jauregizar, Antonio Quintana, Elena Suarez, Ewa Raczka, Leire de la Fuente, Rosario Calvo. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model. Gerontology. 2003 Jul; 49(4):205-14. doi: 10.1159/000070400. [PMID: 12792155]
  • Padmavati Venkataraman, Srinivasan P Venkatachalan, Prasad R Joshi, Mani Muthalagi, Marvin K Schulte. Identification of critical residues in loop E in the 5-HT3ASR binding site. BMC biochemistry. 2002 Jun; 3(?):15. doi: 10.1186/1471-2091-3-15. [PMID: 12079500]
  • Padmavati Venkataraman, Prasad Joshi, Srinivasan P Venkatachalan, Mani Muthalagi, Harish S Parihar, Karen S Kirschbaum, Marvin K Schulte. Functional group interactions of a 5-HT3R antagonist. BMC biochemistry. 2002 Jun; 3(?):16. doi: 10.1186/1471-2091-3-16. [PMID: 12079499]
  • Nerea Jauregizar, Rosario Calvo, Elena Suarez, Antonio Quintana, Ewa Raczka, John C Lukas. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats. Journal of pharmaceutical sciences. 2002 Jan; 91(1):41-52. doi: 10.1002/jps.1169. [PMID: 11782896]
  • N Jauregizar, R Calvo, E Suarez, A Quintana, E Raczka, J C Lukas. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels. Pharmaceutical research. 2001 Jun; 18(6):838-45. doi: 10.1023/a:1011096714860. [PMID: 11474789]
  • R Calvo, R M Jiménez, I F Trocóniz, E Suárez, A Gonzalo, M L Lucero, E Raczka, A Orjales. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer. Cancer chemotherapy and pharmacology. 1998; 42(5):418-22. doi: 10.1007/s002800050839. [PMID: 9771958]